869 research outputs found
Photovoltaic Energy Harvester with Power Management System
We present a photovoltaic energy harvester, realized in 0.35-μm CMOS technology. The proposed system collects light energy from the environment, by means of 2-mm2on-chip integrated microsolar cells, and accumulates it in an external capacitor. While the capacitor is charging, the load is disconnected. When the energy in the external capacitor is enough to operate the load for a predefined time slot, the load is connected to the capacitor by a power management circuit. The choice of the value of the capacitance determines the operating time slot for the load. The proposed solution is suitable for discrete-time-regime applications, such as sensor network nodes, or, in general, systems that require power supply periodically for short time slots. The power management circuit includes a charge pump, a comparator, a level shifter, and a linear voltage regulator. The whole system has been extensively simulated, integrated, and experimentally characterized
Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy
LOFT - a Large Observatory For x-ray Timing
The high time resolution observations of the X-ray sky hold the key to a
number of diagnostics of fundamental physics, some of which are unaccessible to
other types of investigations, such as those based on imaging and spectroscopy.
Revealing strong gravitational field effects, measuring the mass and spin of
black holes and the equation of state of ultradense matter are among the goals
of such observations. At present prospects for future, non-focused X-ray timing
experiments following the exciting age of RXTE/PCA are uncertain. Technological
limitations are unavoidably faced in the conception and development of
experiments with effective area of several square meters, as needed in order to
meet the scientific requirements. We are developing large-area monolithic
Silicon Drift Detectors offering high time and energy resolution at room
temperature, which require modest resources and operation complexity (e.g.,
read-out) per unit area. Based on the properties of the detector and read-out
electronics that we measured in the lab, we developed a realistic concept for a
very large effective area mission devoted to X-ray timing in the 2-30 keV
energy range. We show that effective areas in the range of 10-15 square meters
are within reach, by using a conventional spacecraft platform and launcher of
the small-medium class.Comment: 13 pages, 8 figures, 1 table, Proceedings of SPIE Vol. 7732, Paper
No. 7732-66, 201
Microsystem Technology for Ambient Assisted Living (AAL)
AbstractAAL is certainly an application area with sensor as well as actuator needs. Some of the requirements can be fulfilled by state of the art technology; some areas however still need a lot of R&D efforts for potential applications in homes. The contribution describes two areas of interest and actual development: One is the topic of robust fire detection; the other domain is fall detection. For both application areas one has to understand both the state of the art and the drawbacks of the current solutions. One can state clearly that there is a huge potential for the development of new microsystems. Still one has to keep in mind that usage in elderly homes also requires consent and cooperation of the users which is the focus of the user centered design principle
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
Objective Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Methods Here we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on the grading of 80 contemporary studies for acute leukaemia, chronic leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The aims were (1) to evaluate the scorability of data, (2) to evaluate the reasonableness of the generated grades for clinical benefit using the current version and (3) to identify shortcomings in the ESMO-MCBS v1.1 that require amendments to improve the efficacy and validity of the scale in grading new treatments in the management of haematological malignancies. Results In general, the ESMO-MCBS v1.1 was found to be widely applicable to studies in haematological malignancies, generating scores that were judged as reasonable by European Hematology Association (EHA) experts. A small number of studies could either not be graded or were not appropriately graded. The reasons, related to the differences between haematological and solid tumour malignancies, are identified and described. Conclusions Based on the findings of this study, ESMO and EHA are committed to develop a version of the ESMO-MCBS that is validated for haematological malignancies. This development process will incorporate all of the usual stringencies for accountability of reasonableness that have characterised the development of the ESMO-MCBS including field testing, statistical modelling, evaluation for reasonableness and openness to appeal and revision. Applying such a scale will support future public policy decision-making regarding the value of new treatments for haematological malignancies and will provide insights that could be helpful in the design of future clinical trials
Modeling of Acoustic Emission Failure Mechanism Data from a Unidirectional Fiberglass/Epoxy Tensile Test Specimen
The purpose of this work was to model the acoustic emission (AE) flaw growth data that resulted from the tensile test of a unidirectional fiberglass/epoxy specimen. The data collected and stored during the test were the six standard AE quantification parameters for each event. A classification neural network was used to sort the data into five failure mechanism clusters. The resulting frequency histograms of the sorted data were then mathematically modeled herein using the three types of Johnson distributions: bounded, lognormal, and unbounded. These provided a reasonably good fit for all six AE parameter distributions for each of the five failure mechanisms
The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease
Although iron overload is clinically significant, only limited data have been published on iron overload in haematological diseases. We investigated cardiac and liver iron accumulation by magnetic resonance imaging (MRI) in a cohort of 87 subjects who did not receive chelation, including 59 haematological patients. M-HIC (MRI-based hepatic iron concentration, normal values <36 μmol/g) is a non-invasive, liver biopsy-calibrated method to analyse iron concentration. This method, calibrated to R2 (transverse relaxation rate), was used as a reference standard (M-HIC(R2)). Transfusions and ferritin were evaluated. Mean M-HIC(R2) and cardiac R* of all patients were 142 μmol/g (95% CI, 114–170) and 36.4 1/s (95% CI, 34.2–38.5), respectively. M-HIC(R2) was higher in haematological patients than in patients with chronic liver disease or normal controls (P<0.001). Clearly elevated cardiac R2* was found in two myelodysplastic syndrome (MDS) patients with severe liver iron overload. A poor correlation was found between liver and cardiac iron (n=82, r=0.322, P=0.003), in contrast to a stronger correlation in MDS (n=7, r=0.905, P=0.005). In addition to transfusions, MDS seemed to be an independent factor in iron accumulation. In conclusion, the risk for cardiac iron overload in haematological diseases other than MDS is very low, despite the frequently found liver iron overload
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
- …